Author:
Luan Yunpeng,Li Xiang,Luan Yunqi,Luo Junyu,Dong Qinzuo,Ye Shili,Li Yuejin,Li Yanmei,Jia Lu,Yang Jun,Yang Dong-Hua
Abstract
AbstractPeripheral T-cell lymphoma (PTCL) is a rare and heterogeneous group of hematological malignancies. Compared to our knowledge of B-cell tumors, our understanding of T-cell leukemia and lymphoma remains less advanced, and a significant number of patients are diagnosed with advanced stages of the disease. Unfortunately, the development of drug resistance in tumors leads to relapsed or refractory peripheral T-Cell Lymphomas (r/r PTCL), resulting in highly unsatisfactory treatment outcomes for these patients. This review provides an overview of potential mechanisms contributing to PTCL treatment resistance, encompassing aspects such as tumor heterogeneity, tumor microenvironment, and abnormal signaling pathways in PTCL development. The existing drugs aimed at overcoming PTCL resistance and their potential resistance mechanisms are also discussed. Furthermore, a summary of ongoing clinical trials related to PTCL is presented, with the aim of aiding clinicians in making informed treatment decisions.
Funder
National Natural Science Foundation of China
General Program of Science and Technology Department of Yunnan Provincial
Reserve Talents Project for Young and Middle-aged Academic and Technical Leaders of the Department of Science and Technology of Yunnan Province
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Molecular Medicine